Medolone (Aciclovir)

Aciclovir is a nucleoside analogue that is phosphorylated by viral thymidine kinase and then by cellular enzymes to its active triphosphate form. This active metabolite competitively inhibits viral DNA polymerase, causing premature termination of viral DNA synthesis and halting viral replication.

The dosing regimen for Medolone is determined by the prescribing clinician based on the specific infection, patient weight, renal function, and severity of disease. Healthcare professionals should follow local guidelines and adjust the dose as needed.

Aciclovir’s pregnancy category is not definitively established. It should be used during pregnancy only when the potential benefit justifies the potential risk to the fetus. Limited data are available for breastfeeding; a risk‑benefit assessment should be performed by the prescriber.

To order Medolone, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.

Medolone (intravenous aciclovir) provides rapid systemic exposure, which is advantageous over oral formulations for severe or central nervous system infections. Compared with valacyclovir, it bypasses the need for gastrointestinal absorption and offers more predictable plasma concentrations in critically ill patients.

Medolone should be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Before use, inspect the solution for particulate matter or discoloration and allow it to reach room temperature if required for infusion.

Medolone is given as an intravenous infusion. The infusion rate and duration are determined by the prescriber, usually over 30‑60 minutes, and the product should be diluted with an appropriate compatible IV fluid according to the manufacturer’s instructions.

Serious adverse events include nephrotoxicity, especially with rapid infusion or pre‑existing renal impairment, neurotoxicity such as seizures, severe hypersensitivity reactions (including anaphylaxis), and hematologic abnormalities like thrombocytopenia or hemolytic anemia.

Medolone is contraindicated in patients with known hypersensitivity to aciclovir or any component of the formulation. Caution is advised for individuals with severe renal impairment, and it should be avoided in patients where the risk of severe adverse reactions outweighs therapeutic benefit.